Taylor Boyd
Chief Business OfficerMr. Taylor Boyd is Chief Business Officer of Avalo Therapeutics, Inc. since October 1, 2025. He has experience across biotech business development, corporate finance and investment banking. He was Chief Business Officer of Abzena Limited from 2025 to August 2025. Prior to joining Longboard, Mr. Boyd served as Vice President of Investor Relations at Oxford Biomedica plc. Prior to OXB, Mr. Boyd served as an investment banker covering the biopharmaceutical space for Raymond James, Leerink Partners, Cantor Fitzgerald and RBC Capital Markets. Mr. Boyd was an Associate in Grant Thornton’s Transaction Advisory Services practice. Mr. Boyd earned his B.S. in Accountancy with a concentration in Managerial Accounting from North Carolina State University and his M.S. in Accountancy with a concentration in Transaction Advisory Services from Wake Forest University's Babcock Graduate School of Management.
Positions
- Company NameAvalo Therapeutics, Inc.Stock CodeAVTXPositionChief Business OfficerColleagues
- GAGarry A. NeilPresident, CEO & Director
- MTMichael Thomas HeffernanIndependent Chairman of the Board
- MDMittie DoyleChief Medical Officer
- SHSolomon H. SnyderFounder and Chairman of Scientific Advisory Board
- BSBarbara S. SlusherFounder and Member of Scientific Advisory Board
- SSSamantha Scollard TruexIndependent Director
